Danazol for benign breast disease

Camran Nezhat, Ricardo H. Asch, Robert B. Greenblatt
In: American Journal of Obstetrics and Gynecology · 1980 · vol. 137(5) , pp. 604–607 · doi:10.1016/0002-9378(80)90704-8 · PMID:7386553 · W1589601205
article OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

This paper reviews studies on the use of danazol to treat benign breast disease, examining its efficacy and side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Three groups of women with benign breast disease were treated with danazol for 3 to 6 months. Doses of 100 mg per day were given to 40 patients, 200 mg to 55, and 400 mg to 35. The age range of the patients was 20 to 48 years. The patients were rechecked at 6-month intervals over a period of 48 months. Most of them were seen four or more times after completion of therapy. Elimination of nodularity occurred in about two thirds; three experienced no improvement, and partial resolution was obtained in the remainder. Untoward effects were minimal or trivial. Danazol proved to be an excellent hormonal agent in the management of fibrocystic disease of the breast.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (6)

Source provenance

openalex
last seen: 2026-05-11T04:00:27.769720+00:00
unpaywall
last seen: 2026-09-05T06:29:56.012541+00:00
License: CC0 · commercial use OK